Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Pediatrics/Neonatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Additional Infant Bacterial Therapeutics Product Receives FDA Orphan Drug Designation
Details : IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.
Brand Name : IBP-1016
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 03, 2023
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Pediatrics/Neonatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?